MedTrace Logo

Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis

NCT00666354 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2009-02-10

No results posted yet for this study

Summary

The purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.

Conditions

  • Fingernail Psoriasis

Interventions

DRUG

Methotrexate

0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.

DRUG

Methotrexate

0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.

DRUG

Methotrexate

0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.

Sponsors & Collaborators

  • MediQuest Therapeutics

    lead INDUSTRY

Principal Investigators

  • Prof. Neil McHugh · Royal National Hospital for Rheumatic Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-09-30
Completion
2009-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666354 on ClinicalTrials.gov